7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,849.72

-32.79

-0.04%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Atossa Therapeutics, Inc. (ATOS)

2.1200 +0.1000 (+4.95%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for ATOS

Chart Range Bar

Interval:

In partnership with ChartIQ

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa plans shareholder stake in potential PRV proceeds

Atossa plans shareholder stake in potential PRV proceeds

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

ATOS: Raises up to $16.5 Million in Registered Direct Offering

ATOS: Raises up to $16.5 Million in Registered Direct Offering

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Mobilize your Website

View Site in Mobile | Classic

Share by: